Name of this trial: Origami-2
What type of cancer is this for? Colorectal Cancer
Who is this trial for? Patients with Unresectable or Metastatic Left-sided Colorectal Cancer
What biomarkers are involved? KRAS/NRAS and BRAF Wild-type
What is the National Clinical Trial #? NCT06662786
Brief summary of this trial: Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Need to know: Be diagnosed to have KRAS, NRAS, and BRAF WT tumor as determined by local testing. The last course of adjuvant or neoadjuvant chemotherapy must have concluded >12 months prior to CTC recurrence/metastases.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Oragami-3
What type of cancer is this for? Recurrent Metastatic Colorectal Cancer
Who is this trial for? Patients Who Have Received or Intolerant to Prior Chemotherapy
What biomarkers are involved? Wild-type KRAS/NRAS, BRAF
What is the National Clinical Trial #? NCT06750094
Brief summary of this trial: Randomized, open-label trial of Amivantamab (investigational drug) + chemotherapy, vs. Cetuximab/Bevacizumab (Standard of care, comparator) + chemotherapy, for patients who have recurrent, unresectable or metastatic colorectal cancer.
Need to know: Patients must have received 1 previous line of treatment for metastatic disease, and randomization is 50/50 between the 2 arms of therapy. This is open label, there is no placebo given and patients will know which medications they are receiving. Investigational medication Amivantamab is an injection that goes into abdomen, and will be given weekly for the first cycle, then every 2 weeks in combination with chemotherapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: CODEBREAK 301
What type of cancer is this for? COLON
Phase of this trial? Phase III
Who is this trial for? Men and women with colon cancer that has spread to other parts of the body.
What biomarkers are involved? Your cancer must have a KRAS P.G12C mutation.
What is the National Clinical Trial# NCT04303780
Brief summary of trial: This trial is randomized 1:1 to either Sotorarsib+Panitumumab+FOLFIRI (standard chemo regimen) vs. standard of care chemotherapy regimens FOLFOX or FOLFIRI +/- Avastin. The study is investigating which of these treatment plans shows longer overall survival and progression-free survival in metastatic colon cancer patients.
Need to know: You may have had treatment for your colon cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]